Agenus Inc. (NASDAQ: AGEN) is a clinical-stage biopharmaceutical company that discovers and develops immuno-oncology antibody candidates. Revenue is generated through license agreements, collaboration payments, and royalty financing arrangements with pharmaceutical partners, including Bristol Myers Squibb and Betta Pharmaceuticals. The company has entered into asset sale and license transactions, including agreements with Zydus Life Sciences Limited and Zydus Pharmaceuticals (USA) Inc. signed June 3, 2025. As of December 31, 2025, Agenus held $3.0 million in cash and cash equivalents, down $37.4 million from December 31, 2024, with $45.5 million in principal debt outstanding. The 10-K filed March 16, 2026 discloses substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Since inception, Agenus has expensed $628.0 million in research and development against an estimated $687.0 million in total contracted third-party obligations through December 31, 2025. The company is headquartered in Lexington, Massachusetts.

Revenue model

License fees, collaboration payments, and royalty financing proceeds from pharmaceutical partners. The company also raises capital through at-the-market equity offerings, selling approximately 9.7 million shares for $36.9 million net proceeds during the year ended December 31, 2025.

Products and services

Immuno-oncology antibody candidates in clinical development. Assets sold and licensed to Zydus Life Sciences Limited under agreements dated June 3, 2025. Prior collaboration assets licensed to Bristol Myers Squibb (agreement dated May 17, 2021) and Betta Pharmaceuticals Co., Ltd. (agreement dated June 20, 2020).

Customers and end markets

Pharmaceutical company partners including Bristol Myers Squibb, Betta Pharmaceuticals Co., Ltd., and Zydus Life Sciences Limited. End market is oncology drug development.

Value-chain role

Early-stage drug discoverer and developer that out-licenses or sells antibody assets to larger pharmaceutical companies in exchange for upfront payments, milestones, and royalties.

Geographic exposure

Headquarters in Lexington, Massachusetts. Clinical trials conducted in the United States and the European Economic Area. Licensing agreements with partners in the United States, China (Betta Pharmaceuticals), and India (Zydus Life Sciences).

Source: SEC 10-K, filed 2026-03-16

Industry: Biological Products, (No Diagnostic Substances) Peers: Adicet Bio Inc Altimmune Inc Century Therapeutics Inc Cullinan Therapeutics Inc HilleVax, Inc. Inhibrx, Inc. Kezar Life Sciences Inc Nurix Therapeutics Inc Vera Therapeutics, Inc